ARID1A Loss

CI-VAR-00002483Explore in graph →CIViC 1293

Curated evidence

Evidence by cancer (6 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–6 of 6 evidence items across 4 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Liver Neoplasm1
ARID1A Loss	Sorafenib	Predictive	D	Supports Sensitivity Response	3	submitted	EID7328 Arid1a-deficiency activates Ang2-dependent angiogenesis and promotes HCC progression. Loss of Arid1a in HCCs confers sensitivity to Ang2 blockade and sorafenib treatment. PMID 29113912 · Hu et al., 2018 · Open in CIViC	civic
Malignant Ovarian Neoplasm1
ARID1A Loss	Atezolizumab + Nivolumab + PembrolizumabSubstitutes	Predictive	D	Supports Sensitivity Response	4	submitted	EID6399 Treatment with anti-PD-L1 antibody reduced tumor burden and prolonged survival of mice bearing ARID1A-deficient but not ARID1A-wild-type ovarian tumors. ARID1A deficiency contributes to impaired MMR a…

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Ovarian Clear Cell Adenocarcinoma1
ARID1A Loss	(oncogenic)	Oncogenic	B	Supports Oncogenicity	4	submitted	EID13135 Ovarian clear cell carcinoma is a relatively chemotherapy-refractory ovarian cancer subtype with a comparatively stable genome and a well-recognized association with endometriosis, but the somatic alt… (full text at CIViC) PMID 20942669 · Wiegand et al., 2010 · Open in CIViC	civic

Ovarian Clear Cell Carcinoma3unmapped disease
ARID1A Loss	Dasatinib	Predictive	D	Supports Sensitivity Response	3	accepted	EID2982 High-throughput drug screens in OCCC tumor cell model identified synthetic lethal (SL) interaction between the kinase inhibitor dasatinib and ARID1A mutation. Imposing ARID1A deficiency upon a variet… (full text at CIViC) PMID 27364904 · Miller et al., 2016 · Open in CIViC	civic
ARID1A Loss	GSK126	Predictive	D	Supports Sensitivity Response	4	accepted	EID2983 A screen was performed to identify small molecule inhibitors that inhibit growth of ARID1A inactivated cells using shRNA knockdown in ARID1A wild-type ovarian clear cell carcinoma (OCCC) cell line RMG… (full text at CIViC) PMID 25686104 · Bitler et al., 2015 · Open in CIViC	civic
ARID1A Loss OR ARID1A Wildtype	Dasatinib	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID11789 In this phase 2 clinical study, 28 patients with recurrent Clear Cell Carcinoma of the Ovary, Fallopian Tube, Peritoneum, or Endometrium, harboring either wild-type ARID1A or ARID1A loss were recruite… (full text at CIViC) PMID 37418832 · O'Cearbhaill et al., 2023 · Open in CIViC	civic